Last reviewed · How we verify
Full Boosted Fosamprenavir
Fosamprenavir is a protease inhibitor that, when boosted with ritonavir, blocks HIV protease to prevent viral replication.
Fosamprenavir is a protease inhibitor that, when boosted with ritonavir, blocks HIV protease to prevent viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.
At a glance
| Generic name | Full Boosted Fosamprenavir |
|---|---|
| Also known as | Fosamprenavir, ritonavir |
| Sponsor | GlaxoSmithKline |
| Drug class | HIV protease inhibitor |
| Target | HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Fosamprenavir is a prodrug that is converted to amprenavir in vivo. It inhibits HIV protease, an enzyme essential for processing viral polyproteins into functional components. When combined with ritonavir (a pharmacokinetic booster), ritonavir inhibits cytochrome P450 metabolism, increasing fosamprenavir plasma concentrations and allowing for improved dosing convenience and efficacy.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients
Common side effects
- Diarrhea
- Nausea
- Headache
- Rash
- Vomiting
- Hyperglycemia
- Lipid abnormalities
Key clinical trials
- A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Full Boosted Fosamprenavir CI brief — competitive landscape report
- Full Boosted Fosamprenavir updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI